Dimiter V. Tassev, PhD

Director, Business Development & Licensing Oncology, Immuno-Oncology Search and Evaluation at Merck, New York, NY

For Research Scientists
Research Programs
Research Areas
Education & Training
Our Research Advantage

Dimiter V. Tassev, PhD

Director, Business Development & Licensing Oncology, Immuno-Oncology Search and Evaluation at Merck, New York, NY

Share
Print
Share
Print
Dimiter V. Tassev

Dissertation

Generation and Use of HLA-A2-Restricted, Peptide-Specific Monoclonal Antibodies and Chimeric Antigen Receptors

Mentor

Nai-Kong V. Cheung, MD, PhD

End Year

2011

Education

The Ohio State University

Publications

Zhao Q, Ahmed M, Tassev DV, Hasan A, Kuo TY, Guo HF, O’Reilly RJ, Cheung NK. (2015) Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.  Leukemia.

Cheung N, Guo H, Hu J, Tassev D, Cheung I. (2012) Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology, 1, 477-486.

Tassev D, Cheng M, Cheung N. (2011) Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther, 19, 84-100. 

Tassev D, Cheung N. (2009) Monoclonal Antibody Therapies for Solid Tumors. Expert Opin Biol Ther, 9, 341-353.